Palvella Therapeutics, Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -0.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.16 | $-1.52 | -31.0% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.90 | $-1.20 | -33.3% | Miss | |
| Q4 FY25 | $-0.95 | $-1.08 | -13.7% | Miss | |
| Q3 FY25 | $-0.85 | $-1.03 | -21.2% | Miss | |
| Q2 FY25 | $-0.78 | $-0.86 | -10.3% | Miss | Q2 FY25 call |
| Q1 FY25 | not reported | $-0.74 | not reported | not reported | |
| Q3 FY24 | not reported | $-2.19 | not reported | not reported | |
| Q2 FY24 | not reported | $-2.76 | not reported | not reported | |
| Q1 FY24 | not reported | $-3.95 | not reported | not reported | |
| Q4 FY23 | not reported | $-0.05 | not reported | not reported | |
| Q3 FY23 | $-0.11 | $-0.11 | +0.0% | Beat | |
| Q2 FY23 | not reported | $0.05 | not reported | not reported |
Back to PVLA overview · PVLA holders · PVLA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.